Journal of Nanomaterials / 2013 / Article / Tab 1

Review Article

Nanotechnological Advances in Cutaneous Medicine

Table 1

The use of nanoparticle technology for delivery of drugs transcutaneously targeting the most common cutaneous pathologies.

Nanoparticle typeDrugSkin typeStudyDelivery type and penetrationTargeted cutaneous disease pathologyLiterature studies

Solid lipid nanoparticleGlucocorticoids, corticosteroidsHumanIn vitro and in vivoTransepidermal delivery, no penetration to the dermisInflammatory skin diseases, dermatitis, rheumatic diseaseSivaramakrishnan et al., 2004 [24]; Jensen et al., 2010 [25]; Zhang and Smith, 2011 [26]; Schlupp et al., 2011 [27]; Puglia et al., 2006 [28]
Solid lipid nanoparticleNonsteroidal anti-inflammatory drugsHumanIn vitro and in vivoDelivery via NP enriched hydrogels with sustained continued drug release to the dermisMusculoskeletal disordersJain et al., 2005 [29]; Bhaskar et al., 2009 [30]
Solid lipid nanoparticleAntiandrogens, retinoidsHumanIn vitro and in vivoTransappendageal NP delivery to hair follicle and upper papillary dermisSkin acneMunster et al., 2005 [31]; Štecová et al., 2007 [32]; Castro et al., 2007 [33]
Solid lipid nanoparticleAntifungal agentsHumanEx vivo and in vivoTopical gel delivery of NP with penetration to upper papillary dermisSkin mycosesBhalekar et al., 2009 [34]; Sanna et al., 2007 [35]
Solid lipid nanoparticleRetinoids, furocoumarinsMouse and humanIn vivoTopical gel delivery to the epidermisPsoriasisFang et al., 2008 [19]; Agrawal et al., 2010 [15];
Lin et al., 2010 [36]
Solid lipid nanoparticleTacrolimusPorcineIn vitro and in vivoTopical gel delivery with dermal penetrationAtopic dermatitisPople and Singh, 2010 [37]
Nanostructured lipid carriersAntihypersensitive drugs and anaestheticsMouse and humanIn vitro and in vivoTopical gel delivery to the epidermisHair loss treatment and pain relief after surgerySilva et al., 2009 [38]; Puglia et al., 2011 [39]

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.